Precision oncology care firm Cureety has acquired artificial intelligence-powered cancer care organization Reimagine Care, bringing together two platforms focused on delivering more continuous and personalized support to patients undergoing cancer treatment.
The combination expands the companies’ collective reach to more than 250 cancer centers and over 100,000 patients across five countries, according to the announcement made September 2.
Cureety developed its technology specifically for oncology, incorporating treatment-specific monitoring and triage capabilities that allow care teams to identify signs of patient deterioration and determine which cases require attention. Its digital workflows also aim to reduce administrative workloads.
Reimagine Care works with healthcare providers and health systems as an extension of oncology practices, giving patients access to a virtual care center and Remi, an AI-powered virtual assistant that provides round-the-clock triage and support. Its platform also connects patients with oncology-trained clinicians at any time and can virtually address approximately 95% of patient needs.
The acquisition comes as oncology treatment becomes increasingly individualized and complicated, with more care shifting beyond traditional hospital settings. At the same time, cancer teams are managing expanding patient populations while operating with constrained clinical resources.
Reimagine Care Chief Executive Officer Dan Nardi said the company has spent roughly a decade helping make cancer treatment substantially more sophisticated, but argued that the infrastructure surrounding those therapies has not advanced at the same pace. He said the problem becomes increasingly difficult to ignore as treatments grow more complex and that healthcare teams should be able to identify meaningful changes in a patient’s condition based on their specific therapy and intervene before an emergency department visit or unplanned appointment becomes necessary.
Nardi said Cureety has developed its platform around understanding the clinical nuances associated with individual cancer treatments. He added that combining those capabilities with Reimagine Care’s ability to reach patients continuously through an AI-supported care layer could make ongoing oncology support both more clinically valuable and easier to scale.
The companies did not disclose the financial terms of the acquisition.
Cureety Chief Operating Officer Misha Kaur said some of the most valuable applications of AI in healthcare may involve relatively simple tasks, such as asking patients the right questions and identifying meaningful deviations from their usual health status.
Kaur said the combination of Reimagine Care’s AI technology with Cureety’s clinical expertise should be judged not by whether an AI system can conduct an impressive conversation, but by whether it can provide the appropriate human clinician with the right information at the right time. She emphasized that the objective is to enhance human-delivered care rather than replace it, making that care more timely, informed and accessible when intervention is most important.
In May, Reimagine Care announced an expansion of its AI-supported virtual oncology program through a collaboration with Moffitt Cancer Center.
During the program’s initial implementation, the virtual care model handled nearly 7,000 patient interactions, with 97% resolved independently without escalation to healthcare providers. Symptom-management cases were resolved virtually in 94% of instances, while under 2.5% of interactions resulted in emergency department referrals.
Cureety has acquired U.S.-based Reimagine Care, bringing together precision oncology monitoring, artificial intelligence, virtual care, and specialized oncology teams. The transaction was announced on September 2, 2026, with financial terms not disclosed.
The combination is designed to extend cancer care beyond traditional clinic visits and create a more continuous model of patient support.
Cureety Expands Its Oncology Platform
Cureety specializes in precision oncology care and remote monitoring. Its platform uses therapy-specific monitoring and clinical intelligence to help healthcare teams identify changes in patient conditions and prioritize patients who may need attention.
By acquiring Reimagine Care, Cureety adds AI-supported patient engagement and virtual oncology care capabilities to its existing platform.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
